ATE442161T1 - Botulinumneurotoxin-b-rezeptoren und ihreverwendung - Google Patents

Botulinumneurotoxin-b-rezeptoren und ihreverwendung

Info

Publication number
ATE442161T1
ATE442161T1 AT03816739T AT03816739T ATE442161T1 AT E442161 T1 ATE442161 T1 AT E442161T1 AT 03816739 T AT03816739 T AT 03816739T AT 03816739 T AT03816739 T AT 03816739T AT E442161 T1 ATE442161 T1 AT E442161T1
Authority
AT
Austria
Prior art keywords
bont
syt
methods
binding
disclosed
Prior art date
Application number
AT03816739T
Other languages
English (en)
Inventor
Edwin Chapman
Min Dong
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE442161T1 publication Critical patent/ATE442161T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03816739T 2002-10-31 2003-10-28 Botulinumneurotoxin-b-rezeptoren und ihreverwendung ATE442161T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42295102P 2002-10-31 2002-10-31
US49812803P 2003-08-27 2003-08-27
PCT/US2003/034348 WO2005016233A2 (en) 2002-10-31 2003-10-28 Botulinum neurotoxin b receptors and use thereof

Publications (1)

Publication Number Publication Date
ATE442161T1 true ATE442161T1 (de) 2009-09-15

Family

ID=34197667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03816739T ATE442161T1 (de) 2002-10-31 2003-10-28 Botulinumneurotoxin-b-rezeptoren und ihreverwendung

Country Status (10)

Country Link
US (2) US20040191887A1 (de)
EP (1) EP1578382B1 (de)
JP (2) JP2006512090A (de)
AT (1) ATE442161T1 (de)
AU (1) AU2003304419A1 (de)
CA (1) CA2504532C (de)
DE (1) DE60329225D1 (de)
ES (1) ES2333319T3 (de)
IL (1) IL167943A (de)
WO (1) WO2005016233A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333319T3 (es) * 2002-10-31 2010-02-19 Wisconsin Alumni Research Foundation Receptores de la neurotoxina botulinica b y su uso.
US7341843B2 (en) * 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US8748106B2 (en) * 2005-04-18 2014-06-10 Bal Ram Singh Methods of identifying a compound that increases or decreases the interaction of Hn-33 with synaptotagmin II
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
EP2208067B1 (de) 2007-09-14 2019-02-06 BioMadison, Inc. Resonanzenergietransfer-testverfahren mit spaltsequenz und spacer
US11325954B2 (en) 2011-06-01 2022-05-10 Biomadison, Inc. Compositions and methods for stability testing of botulinum toxin
EP2715355B1 (de) 2011-06-01 2017-03-08 Biomadison, Inc. Nicht auf "fret" beruhender botulismusassay
US10908146B2 (en) 2011-06-01 2021-02-02 Biomadison, Inc. Compositions and methods for improving sensitivity in cell based assays
US9303285B2 (en) 2012-01-04 2016-04-05 Biomadison, Inc. Methods and compounds for increasing sensitivity of botulinum assays
ES2818986T5 (es) 2013-08-09 2024-01-25 Biomadison Inc Ensayo de toxina botulínica con sensibilidad mejorada
WO2023210585A1 (ja) * 2022-04-25 2023-11-02 株式会社Jiksak Bioengineering 標的化剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994995B1 (en) * 2001-03-16 2006-02-07 Lexicon Genetics Incorporated Human synaptotagmin and polynucleotides encoding the same
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
ES2333319T3 (es) * 2002-10-31 2010-02-19 Wisconsin Alumni Research Foundation Receptores de la neurotoxina botulinica b y su uso.
EP2502930B1 (de) * 2003-12-19 2016-06-29 Wisconsin Alumni Research Foundation Verfahren und zusammensetzungen zum nachweis von botulinum-neurotoxin
ATE483158T1 (de) * 2005-04-05 2010-10-15 Allergan Inc Clostridientoxinaktivitätstests
ES2426194T3 (es) * 2005-08-02 2013-10-21 Planet Biotechnology, Inc. Proteínas quiméricas del receptor de toxina mejoradas y proteínas quiméricas del receptor de toxina para el tratamiento y la prevención de anthrax
US7985554B2 (en) * 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
WO2013011055A1 (en) * 2011-07-19 2013-01-24 ETH Zürich Means and methods for determining clostridial neurotoxins

Also Published As

Publication number Publication date
EP1578382A2 (de) 2005-09-28
DE60329225D1 (de) 2009-10-22
JP2006512090A (ja) 2006-04-13
IL167943A (en) 2010-12-30
US20120082672A1 (en) 2012-04-05
CA2504532C (en) 2014-09-16
JP2010006833A (ja) 2010-01-14
AU2003304419A1 (en) 2005-03-07
EP1578382A4 (de) 2007-08-29
ES2333319T3 (es) 2010-02-19
EP1578382B1 (de) 2009-09-09
CA2504532A1 (en) 2005-02-24
US20040191887A1 (en) 2004-09-30
US8617573B2 (en) 2013-12-31
WO2005016233A3 (en) 2005-08-18
AU2003304419A8 (en) 2005-03-07
WO2005016233A2 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
IL167943A (en) Botulinum neurotoxin b receptors and use thereof
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CY1122686T1 (el) Ανταγωνιστικοι εκλεκτικοι παραγοντες συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης
DE59910084D1 (de) Organische Salze von Isoleucyl-Thiazolidin und -Pyrrolidin und ihre Verwendung als Dipeptidylpeptidase-Inhibitoren
DE602004006433D1 (de) Pyrrol-substituierte indole als inhibitoren von pai-1
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
ATE544473T1 (de) Chimäre moleküle zur modulation der genexpression
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
ATE466080T1 (de) Formulierungen und verfahren zum denaturieren von proteinen
DE60100620D1 (de) Gezielte elektrochemische reduktion von halogenierten 4-amino-picolinsäuren
ATE466283T1 (de) Zentrifugalvorrichtung und verfahren zur durchführung von bindungsversuchen
DE60139544D1 (de) Veränderte, fluoreszierende proteine
ATE383172T1 (de) Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden
DE60129137D1 (de) Modulierung durch il-tif/interleukin-21
DE60107416D1 (de) Adnf mischungen zur verbesserung der lernfähigkeit und der gedächtnisfunktion
ATE487792T1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
DE60332029D1 (de) Screening-verfahren für kognitive erweiterungsvorrichtungen
BRPI0414283A (pt) métodos, composições e kits para a concentração e detecção de microorganismos
ATE520028T1 (de) Test zum nachweis von proteinbindung
DE60332756D1 (de) Anti-infarkt-moleküle
ATE450625T1 (de) Zweifaches hybridsystem
DE60332479D1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
ATE435200T1 (de) Guanidinophenylalanin-verbindungen als urokinase- inhibitoren
DE50113417D1 (de) Zellbindende nukleinsäuremoleküle (aptamere)
ATE423977T1 (de) Verfahren mit mikrosomaler prostaglandin-e2- synthase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties